Login

Company Executives

Officer Age In this role 2025 pay Source
Andrew Robbins Also a director
Chief Executive Officer, President and Director
50 Not stated $27,762,684
John Green
Chief Financial Officer
45 Since 2020
6 years
$8,546,329
Evan Kearns
Chief Legal Officer and Corporate Secretary
45 Since 2021
5 years
Not reported
Cole Pinnow
Chief Commercial Officer
51 Since 2024
2 years
$8,839,548
John Robinson
Chief Scientific Officer
52 Since 2021
5 years
$9,150,297
Jessica Sachs
Chief Medical Officer
51 Since 2019
7 years
$9,178,177

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
6.4 years
from year joined
CEO also chairs the board
No
Peter Harwin
Director Age On board Independent Other public boards 2025 pay Source
Peter Harwin
40 2020
6 years
Independent Crescent Biopharma, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc., Oruka Therapeutics, Inc., Damora Therapeutics, Inc., Paragon Therapeutics, Inc. $277,115
Andrew Robbins
50 2020
6 years
Not stated None stated Paid as CEO
Chris Cain
42 2020
6 years
Independent Jade Biosciences, Inc., Viridian Therapeutics, Inc., Damora Therapeutics, Inc. Not stated
Karen Ferrante
68 2018
8 years
Independent MacroGenics, Inc. $247,115
Arlene M. Morris
74 2019
7 years
Independent Palatin Technologies, Inc., Viridian Therapeutics, Inc., Edgewise Therapeutics, Inc. $254,615
Matthew E. Ros
59 2019
7 years
Independent None stated $244,615
Todd Shegog
61 2021
5 years
Independent None stated $257,115

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 23, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support